Objective To systematically review the efficacy of intravitreal injection of anti-vascular endothelial growth factors (anti-VEGF) on macular edema (ME) secondary to retinal vein occlusion (RVO). Methods Databases including PubMed, EMbase, Web of Science, The Cochrane Library, CNKI, WanFang Data and VIP were electronically searched to identify randomized controlled trials on different anti-VEGF drugs in the treatment of RVO-ME from inception to September 17th 2021. Two reviewers independently screened literature, extracted data, and assessed the risk bias of the included studies. Meta-analysis was then performed using RevMan 5.3 software. Results A total of 11 RCTs were included. Data from these studies included 2 436 eyes, of which 1 682 involved central retinal vein occlusion and 754 involved branch retinal vein occlusion. The results of meta-analysis showed that at 6 months of follow-up, anti-VEGF drug treatment of RVO-ME improved corrected visual acuity (MD=14.97, 95%CI 10.09 to 19.86, P<0.000 01) and reduced central retinal thickness (MD= ?218.21, 95%CI ?295.56 to ?140.86, P<0.000 01) compared with control groups. At 12 months, anti-VEGF treatment of RVO-ME showed better improvement in corrected visual acuity compared with control group (MD=5.70, 95%CI 3.90 to 7.50, P<0.000 01). No statistically differences were observed in the improvements corrected visual acuity with different anti-VEGF drugs. However, for central retinal vein occlusion, different anti-VEGF drugs improved the central retinal thickness including aflibercept vs. bevacizumab (MD=?46.79, 95%CI ?83.12 to ?10.46, P=0.01), and bevacizumab vs. ranibizumab (MD=76.03, 95%CI 30.76 to 121.30, P=0.001) had significant differences. Conclusions The current evidence shows that anti-VEGF drugs can improve vision and reduce macular edema in the treatment of RVO-ME. Bevacizumab may be an effective alternative to ranibizumab or aflibercept. Existing evidence cannot determine differences between the improvement of best-corrected vision and the reduction of central retinal thickness during the long-term treatment of RVO, which requires to be verified by further research.
Objective To provide anatomy evidence of the simple injury of the deep branch of the unlar nerve for cl inical diagnosis and treatments. Methods Fifteen fresh samples of voluntary intact amputated forearms with no deformity were observed anatomically, which were mutilated from the distal end of forearm. The midpoint of the forth palm fingerweb wasdefined as dot A , the midpoint of the hook of the hamate bone as dot B, the ulnar margin of the flexor digitorum superficial is of the l ittle finger as OD, and the superficial branch of the unlar nerve and the forth common finger digital nerve as OE, dot O was the vertex of the triangle, dot C was intersection point of a vertical l ine passing dot B toward OE; dot F was the intersection point of CB’s extension l ine and OD. OCF formed a triangle. OCF and the deep branch of the unlar nerve were observed. From May 2000 to June 2007, 3 cases were treated which were all simple injury of the deep branch of the unlar nerve by glass, diagnosed through anatomical observations. The wounds were all located in the hypothenar muscles, and passed through the distal end of the hamate bone. Muscle power controlled by the unlar nerve got lower. The double ends was sewed up in 2 cases directly intra operation, and the superficial branch of radial nerve grafted freely in the other 1 case. Results The distance between dot B and dot O was (19.20 ± 1.30) mm. The length of BC was (7.80 ± 1.35) mm. The morpha of OCF was various, and the route of profundus nervi ulnaris was various in OCF. OCF contains opponens canales mainly. The muscle branch of the hypothenar muscles all send out in front of the opponens canales. The wounds of these 3 cases were all located at the distal end of the hook of the hamate bone, intrinsic muscles controlled by the unlar nerve except hypothenar muscles were restricted without sensory disorder or any other injuries. Three cases were followed up for 2 months to 4 years. Postoperation, the symptoms disappeared, holding power got well, patients’ fingers were nimble. According to the trial standard of the function of the upper l imb peripheral nerve establ ished by Chinese Medieal Surgery of the Hand Association, the synthetical evaluations were excellent.Conclusion Simple injuries of the deep branch of the unlar nerve are all located in OCF; it is not easy to be diagnosed at the early time because of the l ittle wounds, the function of the hypothenar muscles in existence and the normal sense .
The contradiction between the exponential growth of medical knowledge and the delay in traditional evidence synthesis has necessitated the living evidence (LE) synthesis model, which focuses on continuous updates. The concept of LE synthesis has evolved into a dynamic full-lifecycle spectrum ranging from evidence maps and systematic reviews to clinical guidelines. Although the framework by Bendersky et al. established a methodological baseline for regulating this complex system, its reliance on human labor and a "process-driven" logic creates significant efficiency bottlenecks when dealing with massive heterogeneous data. In the context of the technological revolution driven by AI and large language models (LLMs), this paper analyzes the limitations of current frameworks and demonstrates the necessity of evolving from "mechanical process execution" to a paradigm of "human-machine collaborative cognitive augmentation". This shift demands a restructuring of how evidence is discovered and integrated. Furthermore, by combining China's advantages in clinical data resources with current standardization efforts, we explore localized pathways that integrate technological foresight with evidence-based rigor. This aims to build a smart, dynamic evidence ecosystem dedicated to high-quality health decision-making.
ObjectiveTo review the current status of case studies on drug comprehensive clinical evaluation published in China in the past decade, providing references for the standardized implementation of evaluation. MethodsA scoping review was conducted on the published cases of drug comprehensive clinical evaluation in China. The analysis was carried out from themes, dimensions, methods, and quality control. Descriptive analysis was used to analyze the evaluation themes, dimension, method, and quality control of the included studies. Meanwhile, VOSviewer 1.6.20 software was used to conduct co-occurrence network analysis of author's affiliation and evaluation dimensions. ResultsThe research on comprehensive drug clinical evaluation has developed the fastest in Beijing. Medical institutions, universities, and scientific institutions are the main research institutions. Universities and their affiliated hospitals have stronger collaboration, while some local hospitals show research isolation. The evaluation themes focus on chronic diseases and cancer, with some repetitions. The evaluation methods mainly rely on descriptive analysis. In nearly half of the cases, evidence-based medicine methods are inadequately applied. Only about 5% of the cases have conducted real-world research. For cases with the same theme, results may conflict due to differences in methods or data sources. The value integration mainly relies on quantitative scoring, which is lacking in 37.05% cases. Only 14.03% of the cases report quality control. In 31.87% of cases, the data provided by pharmaceutical companies were used, with a lack of conflict-of-interest disclosures. ConclusionAlthough the comprehensive clinical evaluation of drugs in China has developed rapidly, there are problems such as non-standardized methods and differences in data sources. It is necessary to improve the scientificity and decision-making value of evaluation results by coordinating theme selection, strengthening quality control, and developing reporting guideline.